Why the study?
ICIrM represents a diagnostic and therapeutic challenge due to its rarity, heterogeneous presentation, high mortality, and the limitations of current tools, making uniform treatment guidelines inappropriate.
How should immune checkpoint inhibitor myocarditis be treated in adults?
Population
Three illustrative real-life adult cases of ICIrM
Design
Review and case series
Authors
Loading...
Variable ICIrM presentations challenge uniform guidelines; leaves open severity-stratified management strategies.
How should immune checkpoint inhibitor myocarditis be treated in adults?
This review provides a framework for the individualized management of immune checkpoint inhibitor-related myocarditis, highlighting corticosteroids as first-line therapy and immunomodulators for refractory cases.
Badaan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: